Author

J. Y. Chen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 3 Biochemistry· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 3 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1

Frequent Co-Authors

A. C. Mullen· 3 shared C. Sun· 3 shared S. P. Moran· 3 shared W. Li· 3 shared C. Zhou· 2 shared D. Wrobel· 2 shared J. F. Doerner· 2 shared J. F. Rippmann· 2 shared

Activity by Year

2021-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCell Biology

A. C. Mullen

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Screening the human druggable genome identifies ABHD17B as an anti-fibrotic target in hepatic stellate cells

W. Li, R. P. Sparks, C. Sun, Y. Yang, L. Pantano, R. Kirchner, A. Weilheimer, B. J. Toles, J. Y. Chen, S. P. Moran, V. Barrera, Z. Li, P. Zhou, M. L. Brassil, D. Wrobel, , A. C. Mullen

The paper identifies ABHD17B as a therapeutic target for liver fibrosis by showing its depletion inactivates hepatic stellate cells and reduces fibrosis in mice.

bioRxiv · Aug 7, 2023Cell Biology

Conserved long noncoding RNA TILAM promotes liver fibrosis through interaction with PML in hepatic stellate cells

C. Sun, C. Zhou, K. Daneshvar, A. J. Kratkiewicz, A. Ben Saad, A. Hess, J. Y. Chen, J. V. Pondick, S. R. York, W. Li, S. P. Moran, S. Gentile, R. Ur Rahman, Z. Li, R. Sparks, , A. C. Mullen

This study identifies TILAM, a conserved lncRNA that promotes liver fibrosis by interacting with PML in HSCs, and shows its depletion reduces fibrosis in mouse models.

bioRxiv · Jul 29, 2023Cell Biology

A remarkable transformation catalyzed by a domain-of-unknown-function 692 during the biosynthesis of a new RiPP natural product

R. S. Ayikpoe, L. Zhu, J. Y. Chen, C. P. Ting, W. A. van der Donk

This study identifies a new reaction catalyzed by DUF692, a posttranslational modification enzyme, revealing its role in forming a macrocycle and other chemical modifications in a RiPP natural product.

bioRxiv · Feb 6, 2023 · PreprintBiochemistry

Nanchangmycin regulates FYN, FAK and ERK to control the fibrotic activity of hepatic stellate cells

W. Li, J. Y. Chen, C. Sun, R. P. Sparks, L. Pantano, R.-U. Rahman, S. P. Moran, J. V. Pondick, R. Kirchner, D. Wrobel, M. Bieler, S. J. Ho Sui, J. F. Doerner, J. F. Rippmann, A. C. Mullen

This study identifies nanchangmycin as an anti-fibrotic agent that inhibits HSC myofibroblast activity by modulating FYN, FAK, and ERK signaling pathways.

bioRxiv · Oct 8, 2021Cell Biology

A Non-redundant Role for T cell-derived IL-22 in Antibacterial Defense of Colonic Crypts

C. T. Weaver, C. L. Zindl, S. J. Witte, V. A. Laufer, M. Gao, Z. Yue, D. J. Silberger, S. N. Harbour, J. R. Singer, D. Pham, C. E. Moseley, B. Cai, H. Turner, F. E. Lund, B. A. Vallance, , R. D. Hatton

This study shows that T cell-derived IL-22 is essential for antibacterial defense and damage control in intestinal crypts, despite ongoing ILC3-derived IL-22 production.

bioRxiv · May 11, 2021 · PreprintImmunology